New study tracks fabry Drug's Real-World impact on heart and kidneys
NCT ID NCT07109375
First seen Feb 25, 2026 · Last updated May 01, 2026 · Updated 8 times
Summary
This study will follow 75 adults with Fabry disease who are taking or planning to take pegunigalsidase alfa. Researchers will monitor heart structure, kidney function, and exercise capacity over time to see how well the treatment works and how safe it is in real-world settings. The goal is to gather practical information to guide long-term disease management.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AOU Federico II, Dipartimento di Nefrologia
Naples, Italy
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.